Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director · PRESIDENT, CEO AND DIRECTOR | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,499.2826 |
Reported balance
After 2026-10-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-02 · Grant · Acquired 127.6843 · Balance 25,499.2826 F1: Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent. F2: Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F2: Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ELI LILLY & Co
Report date December 31, 2018 · Filed February 01, 2019
Section 16 reporting ended · disclosed 2019-02-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,258 |
Reported balance
After 2018-03-13 transaction · row 1
1 source rowRow 1 · 2018-03-13 · Gift · Disposed 3,200 · Balance 132,258 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 1,093 |
Reported balance
Holding disclosure · report date 2018-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,093 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 4, 2023 02:10 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 12,662 | $11.26 | $142,574.12 |
DisclosureSEC source: 0001415889-23-004289 · form4-03042023_020326.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742,369 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan. F2 · balance_after: Includes 2,045 shares acquired under Elanco Animal Health Inc.'s Employee Stock Purchase Plan on December 30, 2022. Read SEC document |
| September 09, 2022 Filed Sep 9, 2022 20:30 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 30,000 | $14.54 | $436,146.00 |
DisclosureSEC source: 0001415889-22-009497 · form4-09092022_010908.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Indirect · Revocable Trust Disclosed balance after: 30,000 F1 · price: Reflects the weighted average price of 30,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on September 9, 2022 with purchase prices ranging from $14.42 to $14.5576 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:21 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 10,688 | $27.95 | $298,729.60 |
DisclosureSEC source: 0001415889-22-002744 · form4-03082022_010350.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,986 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 02:02 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 8,879 | $29.00 | $257,491.00 |
DisclosureSEC source: 0001415889-22-002472 · form4-03032022_060326.xml · nonDerivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 763,674 F2 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:02 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantEmployee Stock Option(right to buy) · Derivative | 234,160 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001415889-22-002472 · form4-03032022_060326.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,160 Underlying: Common Stock · 234,160 shares Expires 2032-03-01 F3 · derivative.exercise_date: Grant of stock options vesting as follows: one-third vesting on March 1, 2023, one-third vesting on March 1, 2024, and the remaining vesting on March 1, 2025. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:02 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 5,031 | $28.94 | $145,597.14 |
DisclosureSEC source: 0001415889-22-002472 · form4-03032022_060326.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,553 F2 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 02:02 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 88,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-002472 · form4-03032022_060326.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · PRESIDENT, CEO AND DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,584 F1 · shares: Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2022, one-third vesting on March 1, 2023, one-third vesting on March 1, 2024, and the remaining vesting on March 1, 2025. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:40 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 92,948 | $25.98 | $2,414,789.04 |
DisclosureSEC source: 0001179110-22-001597 · edgar.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,470 F2 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of performance-based restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:40 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 229,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001597 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,418 F1 · price: Vesting of performance-based restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 20:22 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 15,814 | $33.66 | $532,299.24 |
DisclosureSEC source: 0001179110-21-009594 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,763 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| August 11, 2021 Filed Aug 11, 2021 17:14 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 16,850 | $29.70 | $500,445.00 |
DisclosureSEC source: 0000950138-21-000410 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,577 F1 · price: These shares were purchased in multiple transactions, all at the price of $29.70. Read SEC document |
| March 05, 2021 Filed Mar 8, 2021 21:24 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 74,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-21-000193 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,727 F1 · price: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 5, 2021, one-third vesting on March 5, 2022, one-third vesting on March 5, 2023, and the remaining vesting on March 5, 2024. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:36 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 8,879 | $32.34 | $287,146.86 |
DisclosureSEC source: 0000950138-21-000170 · edgar.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,353 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 23:36 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 4,883 | $33.65 | $164,312.95 |
DisclosureSEC source: 0000950138-21-000170 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,232 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:56 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 39,180 | $30.58 | $1,198,124.40 |
DisclosureSEC source: 0000950138-21-000152 · edgar.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,115 F2 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of performance-based restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:56 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 89,902 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-21-000152 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,295 F1 · price: Vesting of performance-based restricted stock units granted under the 2018 Elanco Stock Plan. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 13:16 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 14,965 | $29.81 | $446,106.65 |
DisclosureSEC source: 0000950138-21-000087 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,393 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:19 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 33,759 | $30.67 | $1,035,388.53 |
DisclosureSEC source: 0000950138-21-000014 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,358 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:51 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 61,736 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-20-000130 · edgar.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 489,117 F2 · price: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 2, 2020, one-third vesting on March 2, 2021, one-third vesting on March 2, 2022, and the remaining vesting on March 2, 2023. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:51 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 4,883 | $27.40 | $133,794.20 |
DisclosureSEC source: 0000950138-20-000130 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,381 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 22:09 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 34,339 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-20-000095 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,264 F1 · price: Represents the number of performance-based restricted stock units granted under the 2018 Elanco Stock Plan that were earned based on satisfaction of performance criteria. These units remain subject to time-based vesting and may vest on February 1, 2021. Read SEC document |
| February 01, 2020 Filed Feb 4, 2020 21:27 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 28,354 | $30.90 | $876,138.60 |
DisclosureSEC source: 0000950138-20-000053 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,925 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:52 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | Tax withholdingCommon Stock | 43,727 | $29.45 | $1,287,760.15 |
DisclosureSEC source: 0000950138-20-000008 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,279 F1 · shares: Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the 2018 Elanco Stock Plan. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 11:18 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 75,750 | $26.55 | $2,011,162.50 |
DisclosureSEC source: 0001104659-19-048830 · a4.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,006 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.3925 to $26.665, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 22:13 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 264,718 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000152 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,256 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 199,658 vesting on December 31, 2019 and 65,060 vesting on February 1, 2020. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:06 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 37,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000137 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,538 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 60,800 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 37,301 shares of Issuer common stock in exchange for 8,267 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:06 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 33,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000121 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,237 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 22:04 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 109,642 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0000950138-18-000564 · edgar.xml · derivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · Pres., Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,642 Underlying: Elanco Animal Health Inc. Common Stock · 109,642 shares Expires 2028-10-20 F2 · price: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. F2 · derivative.exercise_date: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 22:04 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 36,287 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000564 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Pres., Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,287 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| September 24, 2018 Filed Sep 26, 2018 20:21 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 22,000 | $24.00 | $528,000.00 |
DisclosureSEC source: 0001140361-18-039157 · form4.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · President, CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| May 03, 2018 Filed May 3, 2018 20:34 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 9,027 | $78.50 | $708,619.50 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · nonDerivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,458 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $78.32 to $78.60. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:34 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · derivative · entry 5 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:34 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 8,716 | $81.07 | $706,606.12 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,485 Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:34 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000142 · wf-form4_152537963067006.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2018 Filed Feb 1, 2019 19:09 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-19-000020 · wf-form5_154904812376432.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,258 Read SEC document |
| February 05, 2018 Filed Feb 5, 2018 23:37 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 9,625 | $81.12 | $780,780.00 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · nonDerivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,201 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.80 to $81.43. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · derivative · entry 5 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 9,294 | $81.45 | $756,996.30 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,826 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 23:37 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000076 · wf-form4_151787382601710.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000044 · wf-form4_151744001846526.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Common Stock · 11,111 shares Expires 2019-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 23:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 12,662 | $87.60 | $1,109,191.20 |
DisclosureSEC source: 0000059478-18-000044 · wf-form4_151744001846526.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,794 Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 20:01 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 12,500 | $86.46 | $1,080,750.00 |
DisclosureSEC source: 0000059478-17-000249 · wf-form4_151319528674708.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,522 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 9, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.09 to $86.65. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 22, 2017 Filed Dec 13, 2017 20:01 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 6,390 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000249 · wf-form4_151319528674708.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,132 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:16 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000080 · wf-form4_148615294662173.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,244 shares Expires 2017-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:16 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,731 | $77.03 | $364,428.93 |
DisclosureSEC source: 0000059478-17-000080 · wf-form4_148615294662173.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,022 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 20:16 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 10,244 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000080 · wf-form4_148615294662173.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:27 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 21,326 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-17-000049 · wf-form4_148590508158714.xml · derivative · entry 3 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,326 Underlying: Common Stock · 21,326 shares Expires 2018-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 23:27 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 20,551 | $75.38 | $1,549,134.38 |
DisclosureSEC source: 0000059478-17-000049 · wf-form4_148590508158714.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,509 Read SEC document |
| August 31, 2016 Filed Sep 1, 2016 19:58 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 6,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-16-000416 · wf-form4_147275990864052.xml · derivative · entry 4 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,556 shares Expires 2016-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| August 31, 2016 Filed Sep 1, 2016 19:58 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 3,033 | $77.77 | $235,876.41 |
DisclosureSEC source: 0000059478-16-000416 · wf-form4_147275990864052.xml · nonDerivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · SVP&Pres. Elanco Animal Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,513 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.